Fortress Biotech (FBIO) Financials: History & Chart

Fortress Biotech, Inc.(FBIO)

Biotechnology · Bay Harbor Islands, FL

$2.07-0.02 (-1.20%)

Delayed quote: Oct 6, 2026, 12:25 PM EDT

About Fortress Biotech, Inc.

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.

Bay Harbor Islands, FL

78 employees

www.fortressbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lindsay A. Rosenwald

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	68.47M	18.72M	16.04M	16.08M	17.63M	16.41M	13.14M	15.12M	14.63M
Cost of Goods Sold	25.65M	7.11M	7.34M	5.44M	5.75M	4.94M	4.79M	5.80M	5.29M
Gross Profit	42.81M	11.61M	8.69M	10.64M	11.88M	11.47M	8.35M	9.31M	9.34M
Gross Profit Margin	62.5%	62.0%	54.2%	66.2%	67.4%	69.9%	63.5%	61.6%	63.9%
Total Operating Expenses	72.16M	21.61M	16.43M	15.43M	18.69M	47.95M	30.67M	36.66M	31.44M
Research & Development	1.19M	805K	540K	-367K	208K	8.13M	3.94M	9.94M	9.45M
Selling, General & Administrative	68.84M	20.81M	15.89M	14.73M	17.41M	38.76M	25.66M	26.72M	21.99M
Operating Income (EBIT)	-29.34M	-10.01M	-7.74M	-4.79M	-6.81M	-36.47M	-22.32M	-27.34M	-22.09M
Operating Margin	-42.9%	-53.5%	-48.3%	-29.8%	-38.6%	-222.2%	-169.9%	-180.9%	-151.0%
Income Before Tax (EBT)	145.83M	900K	142.29M	-6.21M	8.85M	-11.65M	-24.69M	-25.98M	-26.63M
Interest Income	3.52M	1.58M	570K	637K	736K	622K	490K	526K	589K
Interest Expense	8.97M	1.48M	3.37M	1.71M	2.42M	2.07M	2.51M	2.59M	6.21M
Other Income/Expense	175.18M	10.90M	150.03M	-1.42M	15.66M	24.82M	-2.37M	1.37M	-4.53M
Net Income	111.82M	-468K	110.37M	-3.94M	5.85M	15.49M	-10.58M	-6.76M	-12.87M
Income Tax Expense	4.64M	298K	5.13M	-816K	26K	0.00	0.00	336K	69K
Net Profit Margin	163.3%	-2.5%	688.2%	-24.5%	33.2%	94.4%	-80.6%	-44.7%	-88.0%
EBITDA	-24.36M	-9.04M	-6.04M	-3.63M	-5.65M	-35.32M	-21.13M	-25.74M	-18.77M
EBITDA Margin	-35.6%	-48.3%	-37.7%	-22.6%	-32.1%	-215.2%	-160.8%	-170.2%	-128.3%
Depreciation & Amortization	4.98M	969K	1.70M	1.16M	1.16M	1.16M	1.19M	1.60M	3.32M
EPS Basic	3.27	-0.08	3.44	-0.22	0.13	0.50	-0.48	-0.37	-0.76
EPS Diluted	2.68	-0.08	2.82	-0.17	0.11	0.45	-0.48	-0.37	-0.76
Weighted Average Basic Shares	31.67M	31.67M	31.54M	27.90M	27.24M	26.88M	26.45M	20.24M	19.70M
Weighted Average Diluted Shares	37.01M	37.01M	38.41M	35.76M	33.10M	29.82M	26.45M	20.24M	19.70M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	63.26M	57.67M	84.51M	75.74M	68.79M	45.60M	36.63M	26.88M
Cost of Goods Sold	20.92M	20.88M	22.89M	30.77M	32.08M	14.59M	10.53M	6.13M
Gross Profit	42.34M	36.80M	61.62M	44.97M	36.71M	31.00M	26.10M	20.76M
Gross Profit Margin	66.9%	63.8%	72.9%	59.4%	53.4%	68.0%	71.2%	77.2%
Total Operating Expenses	112.56M	147.18M	203.96M	248.53M	225.25M	125.28M	136.92M	140.75M
Research & Development	11.90M	56.88M	106.07M	134.88M	128.87M	64.11M	81.33M	87.38M
Selling, General & Administrative	96.40M	87.73M	90.98M	113.66M	86.84M	61.17M	55.59M	53.37M
Operating Income (EBIT)	-70.22M	-110.38M	-142.34M	-203.56M	-188.54M	-94.27M	-110.82M	-120.00M
Operating Margin	-111.0%	-191.4%	-168.4%	-268.8%	-274.1%	-206.7%	-302.5%	-446.4%
Income Before Tax (EBT)	-33.53M	-120.54M	-153.63M	-213.46M	-164.35M	-102.85M	-101.66M	-130.80M
Interest Income	2.48M	2.68M	3.00M	1.40M	649K	1.52M	2.56M	1.10M
Interest Expense	8.71M	9.93M	12.52M	13.64M	15.31M	15.33M	11.85M	10.34M
Other Income/Expense	36.69M	-10.16M	-11.29M	-9.90M	24.19M	-8.58M	9.16M	-10.80M
Net Income	6.82M	-46.00M	-60.64M	-86.58M	-64.70M	-46.53M	-39.96M	-84.15M
Income Tax Expense	-620K	312K	521K	449K	473K	136K	0.00	-463K
Net Profit Margin	10.8%	-79.8%	-71.7%	-114.3%	-94.1%	-102.0%	-109.1%	-313.0%
EBITDA	-65.56M	-105.92M	-136.34M	-194.21M	-181.75M	-88.94M	-106.17M	-117.94M
EBITDA Margin	-103.6%	-183.6%	-161.3%	-256.4%	-264.2%	-195.1%	-289.8%	-438.7%
Depreciation & Amortization	4.66M	4.46M	6.00M	9.35M	6.79M	5.33M	4.65M	2.06M
EPS Basic	-0.07	-2.69	-8.47	-14.55	-11.85	-9.75	-10.95	-29.04
EPS Diluted	-0.05	-2.69	-8.47	-14.55	-11.85	-9.75	-10.95	-29.04
Weighted Average Basic Shares	27.90M	20.78M	8.11M	5.92M	5.45M	4.80M	3.65M	2.90M
Weighted Average Diluted Shares	35.76M	20.78M	8.11M	5.92M	5.45M	4.80M	3.65M	2.90M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.